Company Name: Sage Therapeutics, Inc.
Sage Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is engaged in the development of therapies designed to treat rare central nervous system disorders. The company’s lead product candidate is a treatment for super-refractory status epilepticus (SRSE).
Ticker Symbol: SAGE (NASDAQ)
Company Website: www.sagerx.com
Headquarters: Cambridge, MA